
EquitySector - HealthcareVery High Risk
NAV (11-Nov-26)
Returns (Since Inception)
Fund Size
₹75 Cr
Expense Ratio
0.20%
ISIN
INF209KB10C2
Minimum SIP
-
Exit Load
-
Inception Date
21 Oct 2021
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.74%
+21.46% (Cat Avg.)
3 Years
+21.49%
+22.05% (Cat Avg.)
5 Years
+15.77%
+15.90% (Cat Avg.)
Since Inception
+15.41%
— (Cat Avg.)
| Equity | ₹74.65 Cr | 99.98% |
| Others | ₹0.02 Cr | 0.02% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹12.69 Cr | 17.00% |
| Divi's Laboratories Ltd | Equity | ₹7.81 Cr | 10.46% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹5.56 Cr | 7.45% |
| Laurus Labs Ltd | Equity | ₹5.09 Cr | 6.81% |
| Cipla Ltd | Equity | ₹5 Cr | 6.69% |
| Dr Reddy's Laboratories Ltd | Equity | ₹4.96 Cr | 6.64% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.68 Cr | 6.26% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹4.56 Cr | 6.11% |
| Lupin Ltd | Equity | ₹3.25 Cr | 4.35% |
| Aurobindo Pharma Ltd | Equity | ₹3.05 Cr | 4.08% |
| Fortis Healthcare Ltd | Equity | ₹2.65 Cr | 3.54% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.31 Cr | 3.10% |
| Alkem Laboratories Ltd | Equity | ₹2.07 Cr | 2.77% |
| Zydus Lifesciences Ltd | Equity | ₹1.9 Cr | 2.54% |
| Mankind Pharma Ltd | Equity | ₹1.87 Cr | 2.50% |
| Ipca Laboratories Ltd | Equity | ₹1.76 Cr | 2.36% |
| Biocon Ltd | Equity | ₹1.7 Cr | 2.28% |
| Gland Pharma Ltd | Equity | ₹1.52 Cr | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹1.31 Cr | 1.76% |
| Abbott India Ltd | Equity | ₹0.91 Cr | 1.22% |
| Treps | Cash - Repurchase Agreement | ₹0.53 Cr | 0.71% |
| Net Receivable / Payable | Cash - Collateral | ₹-0.51 Cr | 0.69% |
Large Cap Stocks
47.87%
Mid Cap Stocks
48.31%
Small Cap Stocks
3.80%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹74.66 Cr | 99.98% |
Standard Deviation
This fund
16.45%
Cat. avg.
16.11%
Lower the better
Sharpe Ratio
This fund
0.92
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better
Since July 2026
Since December 2024
ISIN INF209KB10C2 | Expense Ratio 0.20% | Exit Load - | Fund Size ₹75 Cr | Age 5 years | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark NIFTY Healthcare TR TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹4,29,219 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments